CTRI/2022/07/044472招募中未知
A prospective, open-labelled, multicentre, observational registry of ISAR SUMMIT in CAD patients undergoing PCI in real world indian population (TRANSEVER REGISTRY)
Dr Praveen Chandra0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •1. Male or female patient with age > 18 Years
- •2. Patients with coronary artery disease undergoing percutaneous coronary intervention(PCI) with ISAR Summit Polymer Free Everolimus Eluting Coronary Stent System
- •3. Patients or legal guardian who understands the study requirements and can provide informed consent in writing
排除标准
- •1. Concurrent participation in another clinical trial that involves an investigational drug or device
- •2. Participant is pregnant or nursing an infant or child or planning to come pregnant while in the study
- •3. Concurrent medical condition with a life expectancy of less than 12 months
- •4. Known hypersensitivity or contraindication to aspirin, heparin, clopidogrel or ticagrelor, Everolimus or similar drugs,or any other analogue or derivative, cobalt, chromium or contrast media
研究者
相似试验
已完成
不适用
A prospective, open label, multi-centre, observational, post-market study evaluating Juvéderm® Volift with Lidocaine for the correction of moderate to severe nasolabial folds (NLF)gezichtverouderingdermal fillersfacial agingNL-OMON37130Allergan Pharmaceuticals Ireland23
招募中
4 期
Centralized monitoring study for safety of Traditional Chinese Medicine granulesadverse drug reactionITMCTR2000003180First Affiliated Hospital of Guang zhou University of Chinese Medicine
进行中（未招募）
不适用
A prospective, multicentre, open-label, centrally allocated, active-controlled, phase 2 study to evaluate the efficacy and safety of masitinib in combination with gemcitabine versus gemcitabine alone in advanced / metastatic epithelial ovarian cancer patients in second line being refractory to first line platinum treatment or in third lineAdvanced/metastatic epithelial ovarian cancer in second line being refractory to first line platinum treatment or in third lineMedDRA version: 17.1Level: PTClassification code 10033158Term: Ovarian epithelial cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-000491-14-ESAB Science56
招募中
不适用
A prospective, multicenter, open-label, observation study evaluating the efficacy and safety of edoxaban in patients with cancer-associated venous thromboembolismKCT0004697Yonsei University Health System, Severance Hospital300
进行中（未招募）
1 期
Study to evaluate the efficacy and safety of masitinib in combination with gemcitabine versus gemcitabine alone in advanced / metastatic epithelial ovarian cancer patients in second line being refractory to first line platinum treatment or in third line.Advanced/metastatic epithelial ovarian cancer in second line being refractory to first line platinum treatment or in third lineMedDRA version: 20.0 Level: PT Classification code 10033158 Term: Ovarian epithelial cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-000491-14-SKAB Science80